CoChat

Insights from multi-omics integration in complex disease primary tissues

Open access
Kreitmaier, Peter, Katsoula, Georgia, Zeggini, Eleftheria · 2023 · Trends in Genetics
Cited by 161

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Genome-wide association studies (GWAS) have revealed the genetic basis of complex diseases. Integrative studies investigating multi-omics data of disease-relevant primary tissues are needed to refine these insights.By highlighting recent integrative multi-omics studies in relevant tissues of four distinct complex diseases (type 2 diabetes, osteoarthritis, Alzheimer’s disease, and systemic lupus erythematosus), we outline the usefulness of this approach across complex disease types.Multi-omics approaches have extended our biological understanding (e.g., functional interpretation of GWAS signals, construction of new molecular maps) and revealed potential clinically relevant insights (e.g., patient stratification, biomarker identification). Genome-wide association studies (GWAS) have provided insights into the genetic basis of complex diseases. In the next step, integrative multi-omics approaches can characterize molecular profiles in relevant primary tissues to reveal the mechanisms that underlie disease development. Here, we highlight recent progress in four examples of complex diseases generated by integrative studies: type 2 diabetes (T2D), osteoarthritis, Alzheimer’s disease (AD), and systemic lupus erythematosus (SLE). High-resolution methodologies such as single-cell and spatial omics techniques will become even more important in the future. Furthermore, we emphasize the urgent need to include as yet understudied cell types and increase the diversity of studied populations. Genome-wide association studies (GWAS) have provided insights into the genetic basis of complex diseases. In the next step, integrative multi-omics approaches can characterize molecular profiles in relevant primary tissues to reveal the mechanisms that underlie disease development. Here, we highlight recent progress in four examples of complex diseases generated by integrative studies: type 2 diabetes (T2D), osteoarthritis, Alzheimer’s disease (AD), and systemic lupus erythematosus (SLE). High-resolution methodologies such as single-cell and spatial omics techniques will become even more important in the future. Furthermore, we emphasize the urgent need to include as yet understudied cell types and increase the diversity of studied populations. Complex diseases are driven by a combination of multiple environmental and genetic factors. Due to their high prevalence (e.g., osteoarthritis: 40% over the age of 70 years [1.Cui A. et al.Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies.EClinicalMedicine. 2020; 29–30100587Abstract Full Text Full Text PDF PubMed Scopus (327) Google Scholar]; diabetes: 6.28% of the world population [2.Khan M.A.B. et al.Epidemiology of type 2 diabetes - global burden of disease and forecasted trends.J. Epidemiol. Glob. Health. 2020; 10: 107-111Crossref PubMed Google Scholar]), complex diseases represent a substantial burden for public health systems [3.Vos T. et al.Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet. 2020; 396: 1204-1222Abstract Full Text Full Text PDF PubMed Scopus (4846) Google Scholar]. In the context of an aging population, this burden is predicted to increase in the future, underlining the importance of developing effective and personalized treatment methods, including discovery of novel drug targets (especially for drugs that have been approved in another context, referred to as drug repurposing), the identification of biomarkers, and improved patient stratification [4.Zeggini E. et al.Translational genomics and precision medicine: moving from the lab to the clinic.Science. 2019; 365: 1409-1413Crossref PubMed Scopus (86) Google Scholar]. GWAS have identified genetic risk loci implicated in complex diseases and have provided much-needed insights into their complex genetic architecture [5.Buniello A. et al.The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019.Nucleic Acids Res. 2019; 47: D1005-D1012Crossref PubMed Scopus (1935) Google Scholar]. However, translating genetic findings into clinical applications remains challenging across complex diseases. Issues include the strong linkage disequilibrium between variants on risk haplotypes (the actual causal variant of a risk locus often remains elusive) or the identification of effector genes of risk variants, particularly for variants in noncoding regions (see Glossary). Multi-omics data of human primary tissues provide molecular profiles of disease-relevant cell types, thus revealing insights beyond those derived from genetic studies. This molecular information will contribute to overcoming current challenges in translational efforts of complex diseases (Figure 1, Key figure). Briefly, omics data can be integrated with GWAS results to identify target genes of risk variants using causal inference (e.g., Mendelian rand

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tig.2022.08.005

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

Metadata

Authors
Kreitmaier, P., Katsoula, G., & Zeggini, E.
Venue
Trends in Genetics
Publisher
Elsevier BV
Published
2023-01
Volume
39
Issue
1
Pages
46-58
ISSN
0168-9525 (ISSN-L)
OpenAlex
W4296301762
Cited by
161
References
35
FWCI
2.74
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.